CLL

The investigational agent venetoclax has successfully met the primary endpoint of a phase 2 study as a treatment for patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

Adding the targeted drug Imbruvica to a standard combination treatment reduced the risk of disease progression by 80 percent compared with the standard combination alone in patients with pretreated CLL or SLL.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

The efficacy of Imbruvica (ibrutinib) and Zydelig (idelalisib) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.

The vastly improved outlook for patients with chronic lymphocytic leukemia (CLL) was named the American Society of Clinical Oncology's inaugural "Cancer Advance of the Year."

The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.

Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.

Approved and investigational agents have improved outcomes for patients with follicular lymphoma; however a growing understanding of the origins and progression of the disease might offer further insights for future clinical development.

The latest in cancer prevention, diagnosis and treatment.

Gazyva may become a standard treatment for older, sicker patient with CLL.

Updates from the annual meeting of the American Society of Hematology.

The latest in cancer prevention, diagnosis & treatment.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

In an early-phase study, PCI-32765, a BTK inhibitor, was shown to work against CLL, a type of non-Hodgkin lymphoma.

Updates from the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium.

Leukemia is more than just one disease.

A wave of new treatments for chronic lymphocytic leukemia can help keep the disease at bay.

The latest in cancer prevention, diagnosis, and treatment.

Drug news and recent developments

Advances in stem cell transplantation leads to a changing landscape in treating blood cancers, such as lymphoma, leukemia, and multiple myeloma.

The Leukemia and Lymphoma Society's "First Connection" program connects volunteers with newly diagnosed patients and caregivers to help them manage the many aspects of a cancer diagnosis.

Flipping cancer's "off" switch.

News updates from the American Society of Hematology and the San Antonio Breast Cancer Symposium.

Velcade is now available for newly diagnosed multiple myeloma patients and new drugs emerge as potential treatment to a serious side effect.

Discussion of new drugs for CLL and to relieve constipation.

Preventing misdiagnoses of blood cancers is all in the details.

Recent drug approvals yield a new chemotherapy agent, a first for liver cancer, a safer prevention method, and good news for a drug-resistant cancer.

Satraplatin's approval review deadline gets pushed back by the FDA and a large clinical trial shows Vidaza extends survival in patients with MDS.

CML survivor Erin Zammett Ruddy wants a baby. The trade-off may be her health.

Updates from the American Society of Hematology Meeting and the San Antonio Breast Cancer Symposium.